Organization | Grupo Español de Investigación en Neurooncología (GEINO)

Grupo Español de Investigación en Neurooncología (GEINO) Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Founded: Spain (1998)

Organization Overview

First Clinical Trial

2007

NCT01308632

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Grupo Español de Investigación en Neurooncología

Active Ingredients

Drugs in Phase 3 Trials (2)

irinotecan (Camptosar) (1 trial)

temozolomide (temodar) (5 trials)

Drugs in Phase 2 Trials (7)

bevacizumab (avastin) (1 trial)

cannabidiol (Epidiolex) (1 trial)

dacomitinib (vizimpro) (1 trial)

glasdegib (Daurismo) (1 trial)

palbociclib (ibrance) (1 trial)

sunitinib (sutent) (1 trial)

tetrahydrocannabinol (1 trial)

Drugs in Phase 1 Trials (1)

crizotinib (xalkori) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Brain Neoplasms (Phase 2)

Glioblastoma (Phase 3)

Oligodendroglioma (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial APIs: 10